Source: Targeted Oncology, May 2025
Immunotherapy (IO) options can induce durable responses in patients with BRAF-negative metastatic melanoma. Tolerability concerns have determined the use of IO monotherapy vs combination ipilimumab (Yervoy) plus nivolumab (Opdivo), but with the addition of nivolumab plus relatlimab (Opdualag), the role of monotherapy has been questioned due to its comparable tolerability. In a recent virtual Case-Based Roundtable meeting for oncologists in the Great Lakes region, Ahmad Tarhini, MD, PhD, professor of oncologic sciences at the University of South Florida Morsani College of Medicine and director of Cutaneous Clinical and Translational Research and leader of the Neoadjuvant and Adjuvant Translational Science Program at Moffitt Cancer Center, surveyed participants on the use of combination vs monotherapy IO regimens in different disease settings.